Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

ICU Topicsrenal-metabolic

ICU · renal-metabolic

Rheumatological Emergencies in the ICU

Also known as Rheumatological emergencies · Scleroderma renal crisis · Systemic sclerosis renal crisis · Neuropsychiatric lupus · Lupus cerebritis · Antisynthetase syndrome · Inflammatory myositis ICU · Rheumatoid vasculitis · Connective tissue disease in ICU · Autoimmune emergency ICU

Rheumatological emergencies in the ICU — life-threatening presentations of systemic autoimmune diseases requiring critical care: (1) scleroderma renal crisis (SRC — sudden malignant hypertension + AKI + microangiopathic haemolysis in diffuse cutaneous systemic sclerosis — ACE inhibitor is LIFE-SAVING), (2) SLE emergencies (neuropsychiatric lupus — seizures, psychosis, transverse myelitis; lupus pneumonitis; lupus nephritis with RPGN; catastrophic antiphospholipid syndrome), (3) inflammatory myopathy with interstitial lung disease (antisynthetase syndrome — anti-Jo-1, anti-MDA5 — rapidly progressive ILD), (4) rheumatoid vasculitis and atlantoaxial subluxation, (5) adult-onset Still disease with MAS. Management: ACE inhibition, pulse methylprednisolone with cyclophosphamide, triple immunosuppression for anti-MDA5 RP-ILD, difficult-airway anticipation in RA, and PAH-targeted therapy in systemic sclerosis.

high33 referencesUpdated 17 Aug 202625 min readSource-verified · Sept 2026

Checked against its sources on 2 Sept 2026

Practise this topic

  • 8 MCQs

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

CICMFFICMEDIC

Red flags

  • Scleroderma renal crisis: sudden malignant hypertension + AKI + microangiopathic haemolysis in systemic sclerosis = START AND UPTITRATE AN ACE INHIBITOR IMMEDIATELY — this is the ONE intervention that changes outcome
  • Anti-MDA5 dermatomyositis: rapidly progressive ILD (within days-weeks) with high mortality — high-dose steroids + calcineurin inhibitor ± cyclophosphamide early — check anti-MDA5 and ferritin in ANY patient with rapidly progressive ILD + Gottron papules/mechanic's hands
  • Neuropsychiatric lupus: seizures, psychosis, transverse myelitis, or cognitive dysfunction in SLE = pulse methylprednisolone + cyclophosphamide — distinguish from steroid-induced neuropsychiatric effects (dose-related, recover when the steroid dose falls)
  • Atlantoaxial subluxation in RA: neck pain + neurological symptoms + RA = flexion-extension X-ray/MRI BEFORE intubation — in-line stabilisation during laryngoscopy — anterior subluxation can compress spinal cord during neck extension for intubation
  • Cricoarytenoid arthritis in RA: hoarseness + stridor + RA = difficult airway — fiberoptic intubation preferred — cricothyroidotomy may be anatomically distorted
  • Systemic sclerosis + refractory hypoxaemia: screen for pulmonary arterial hypertension with annual echo (SSc accounts for most CTD-associated PAH) — right heart catheter for confirmation
  • DO NOT withhold ACE inhibitor in scleroderma renal crisis even if creatinine rises — with ACE inhibitors 1-year survival is 76% versus 15% without, and over half of patients still on dialysis after 3 months who continue the ACE inhibitor come off dialysis — a rising creatinine is NOT a reason to stop
On this page
Study tools

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

CICMFFICMEDIC

Red flags

  • Scleroderma renal crisis: sudden malignant hypertension + AKI + microangiopathic haemolysis in systemic sclerosis = START AND UPTITRATE AN ACE INHIBITOR IMMEDIATELY — this is the ONE intervention that changes outcome
  • Anti-MDA5 dermatomyositis: rapidly progressive ILD (within days-weeks) with high mortality — high-dose steroids + calcineurin inhibitor ± cyclophosphamide early — check anti-MDA5 and ferritin in ANY patient with rapidly progressive ILD + Gottron papules/mechanic's hands
  • Neuropsychiatric lupus: seizures, psychosis, transverse myelitis, or cognitive dysfunction in SLE = pulse methylprednisolone + cyclophosphamide — distinguish from steroid-induced neuropsychiatric effects (dose-related, recover when the steroid dose falls)
  • Atlantoaxial subluxation in RA: neck pain + neurological symptoms + RA = flexion-extension X-ray/MRI BEFORE intubation — in-line stabilisation during laryngoscopy — anterior subluxation can compress spinal cord during neck extension for intubation
  • Cricoarytenoid arthritis in RA: hoarseness + stridor + RA = difficult airway — fiberoptic intubation preferred — cricothyroidotomy may be anatomically distorted
  • Systemic sclerosis + refractory hypoxaemia: screen for pulmonary arterial hypertension with annual echo (SSc accounts for most CTD-associated PAH) — right heart catheter for confirmation
  • DO NOT withhold ACE inhibitor in scleroderma renal crisis even if creatinine rises — with ACE inhibitors 1-year survival is 76% versus 15% without, and over half of patients still on dialysis after 3 months who continue the ACE inhibitor come off dialysis — a rising creatinine is NOT a reason to stop
The one-paragraph exam answer

Five autoimmune crises earn an ICU bed, and each has one move that decides who goes home. Scleroderma renal crisis (SRC) — sudden malignant hypertension plus AKI plus schistocytes in diffuse cutaneous systemic sclerosis — the ACE inhibitor, started immediately and uptitrated, is the one disease-modifying drug (1-year survival 76% with an ACE inhibitor versus 15% without), and you never stop it for a rising creatinine.[1][2] Neuropsychiatric lupus — once infection and drugs are excluded — is pulse IV methylprednisolone (3 g induction) plus cyclophosphamide, with the steroid-versus-lupus-neuropsychiatric distinction deciding whether you increase or taper.[8] Anti-MDA5 dermatomyositis with rapidly progressive ILD gets combination therapy (high-dose glucocorticoids plus a calcineurin inhibitor, with or without cyclophosphamide) within hours.[14] The rheumatoid airway gets anticipated — image the cervical spine before you intubate.[19] SSc pulmonary hypertension gets screened annually with echo and confirmed by right heart catheter.[24][25]

Meet the patient

A 47-year-old woman with diffuse cutaneous systemic sclerosis, started on prednisone 30 mg daily two weeks ago for progressive interstitial lung disease, arrives on your unit with a thunderclap headache and blurred vision. BP 196 over 118, fundi show flame haemorrhages, creatinine has jumped from a baseline of 78 to 186, and the blood film is full of schistocytes. The registrar reaches for amlodipine.[1]

That reach is moment exam question lives or dies. The two questions that decide her next 24 hours are the two that decide every rheumatology emergency: is this a disease-specific crisis with a disease-specific drug? (yes — scleroderma renal crisis, and the drug is an ACE inhibitor), and will you persist with that drug when the creatinine climbs? (you will — because renal function recovers in most survivors who persist, and stopping is how patients stay on dialysis). Hold those two questions and the whole topic slots into place.[2][3]

[7]
ICU Fellowship (CICM) Pro

Continue reading

You have read the opening of this topic. The complete unit — every section and its primary-source references — is part of the ICU Fellowship (CICM) fellowship library.

Sign in to continueSee pricing
References33ShowHide
  1. [1]Steen VD, Medsger TA Jr Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis Arthritis Rheum, 1998.PMID 9751093
  2. [2]Steen VD, Costantino JP, Shapiro AP, et al. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors Ann Intern Med, 1990.PMID 2382917
  3. [3]Penn H, Howie AJ, Kingdon EJ, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes QJM, 2007.PMID 17601770
  4. [4]DeMarco PJ, Weisman MH, Seibold JR, et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial Arthritis Rheum, 2002.PMID 12428241
  5. [5]Chrabaszcz M, Małyszko J, Sikora M, et al. Renal Involvement in Systemic Sclerosis: An Update Kidney Blood Press Res, 2020.PMID 32521536
  6. [6]The American College of Rheumatology Nomenclature Committee on Neuropsychiatric Lupus Syndromes The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes Arthritis Rheum, 1999.PMID 10211873
  7. [7]Hanly JG, Gordon C, Bae SC, et al. Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort Arthritis Rheumatol, 2021.PMID 34042329
  8. [8]Barile-Fabris L, Ariza-Andraca R, Olguín-Ortega L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus Ann Rheum Dis, 2005.PMID 15769918
  9. [9]Dubovsky AN, Arvikar S, Stern TA, et al. The neuropsychiatric complications of glucocorticoid use: steroid psychosis revisited Psychosomatics, 2012.PMID 22424158
  10. [10]Salter BM, Crowther MA Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease Hematology Am Soc Hematol Educ Program, 2024.PMID 39644034
  11. [11]Patel P, Marinock JM, Ajmeri A, et al. A Review of Antisynthetase Syndrome-Associated Interstitial Lung Disease Int J Mol Sci, 2024.PMID 38674039
  12. [12]Kouranloo K, Dey M, Elwell H, et al. Management and outcomes of interstitial lung disease associated with anti-synthetase syndrome: a systematic literature review Rheumatology (Oxford), 2025.PMID 39083028
  13. [13]Matsuda KM, Yoshizaki A, Kuzumi A, et al. Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis J Dermatol, 2020.PMID 32096271
  14. [14]Romero-Bueno F, Diaz Del Campo P, Trallero-Araguás E, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease Semin Arthritis Rheum, 2020.PMID 32534273
  15. [15]Liu T, Ji X, Wei Y, et al. Predictors of rapidly progressive interstitial lung disease in anti-MDA5 dermatomyositis: a meta-analysis Rheumatology (Oxford), 2026.PMID 42334960
  16. [16]Yang B, Tong Z Prognostic factors and a nomogram for survival in anti-MDA5 antibody-positive dermatomyositis-associated interstitial lung disease BMC Pulm Med, 2025.PMID 41366363
  17. [17]Yamaguchi K Clinical features, pathogenesis, and treatment of anti-MDA5 antibody-positive interstitial lung disease Respir Investig, 2026.PMID 42127706
  18. [18]Mogyoróssy S, Griger Z, Tarr T, et al. Management and Prognosis of Anti-MDA5 Dermatomyositis: Insights from a National Multicenter Cohort Biomedicines, 2026.PMID 41898353
  19. [19]Lopez-Olivo MA, Andrabi TR, Palla SL, et al. Cervical spine radiographs in patients with rheumatoid arthritis undergoing anesthesia J Clin Rheumatol, 2012.PMID 22334269
  20. [20]Iacovou E, Vlastarakos PV, Nikolopoulos TP Laryngeal Involvement in Connective Tissue Disorders. Is it Important for Patient Management? Indian J Otolaryngol Head Neck Surg, 2014.PMID 24533356
  21. [21]Minoda SS, Sada RM, Akebo H, et al. New perspective on the clinical and laboratory characteristics of rheumatoid pleural effusion: A 29-case series Mod Rheumatol, 2025.PMID 39172636
  22. [22]Ouellette S, Shah R, Razi S, et al. Fatal low-dose methotrexate toxicity: A case report and literature review Dermatol Ther, 2022.PMID 36259229
  23. [23]Hall JJ, Bolina M, Chatterley T, et al. Interaction Between Low-Dose Methotrexate and Nonsteroidal Anti-inflammatory Drugs, Penicillins, and Proton Pump Inhibitors Ann Pharmacother, 2017.PMID 27701081
  24. [24]Cansu DÜ, Korkmaz C Pulmonary hypertension in connective tissue diseases: epidemiology, pathogenesis, and treatment Clin Rheumatol, 2023.PMID 36396789
  25. [25]Grygiel-Górniak B, Lucki M, Daroszewski P, et al. Insights into Pulmonary Arterial Hypertension in Connective Tissue Diseases J Clin Med, 2025.PMID 40649115
  26. [26]Visovatti SH, Distler O, Coghlan JG, et al. Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study Arthritis Res Ther, 2014.PMID 25491468
  27. [27]Distler O, Highland KB, Gahlemann M, et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease N Engl J Med, 2019.PMID 31112379
  28. [28]Esposito AJ, Selvan KC, Richardson C, et al. Systemic Sclerosis-Associated Interstitial Lung Disease: What We Know and How to Incorporate Guidelines Into Clinical Practice Chest, 2025.PMID 41397518
  29. [29]Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide Arthritis Rheum, 2002.PMID 12209517
  30. [30]Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide Ann Rheum Dis, 2010.PMID 19155235
  31. [31]Guérin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome N Engl J Med, 2013.PMID 23688302
  32. [32]Brower RG, Matthay MA, Morris A, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome N Engl J Med, 2000.PMID 10793162
  33. [33]Ercan Emreol H, Sag E, Ozcilingir Hakverdi P, et al. Clinical course, complications and treatment outcomes in Still's disease: a 10-year single-centre cohort study RMD Open, 2026.PMID 42120178

Test yourself

Practise what you just read

  • 8 MCQs
ICU Fellowship (CICM) Pro

$29/ monthor $279 / year

The complete ICU Fellowship (CICM) library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousRhabdomyolysis in the ICURenal/MetabolicNextSystematic Arterial Blood Gas Interpretation — Comprehensiverenal-metabolic